• Bioxyne signs agreement with Aurora Cannabis for production of cannabis-based products
• Initial purchase orders received for over 5,000 sublingual oil products and 20,000 vape products
• Expected production revenue of $3-$5 million over the next 12 months

Bioxyne Ltd (ASX: BXN), an Australian-headquartered international consumer health and pharmaceutical company, has announced a manufacturing agreement with Aurora Cannabis Inc. (Nasdaq/TSX: ACB), a global leader in medical cannabis. The agreement covers the full breadth of products produced by Bioxyne, and the company has already received purchase orders for 2 product SKUs of over 5,000 sublingual oil products and over 20,000 vape products for delivery into the Australian and UK markets. In addition, purchase orders have been received for 2 Pastille/gummie SKUs. Bioxyne expects this production relationship to result in excess of $3 to $5 million in production revenue over the next 12 months as the volume and scope of production grows. The agreement does not change the market guidance provided by Bioxyne on 26 February 2026.

Bioxyne expects this production relationship with Aurora Cannabis to result in excess of $3 to $5 million in production revenue over the next 12 months.